BioNTech SE - ADR Stock News

MAINZ, Germany, October 13, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the first topline results from the AHEAD-MERIT Phase 2/3 clinical trial (NCT04534205) for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or “tenu-ra”).

German COVID‑19 vaccine maker BioNTech said on Monday it would close ​sites in Germany and Singapore because ‌it failed to find buyers after pivoting away from pandemic-era manufacturing.

BioNTech said on Monday ​that a late-stage ‌trial showed its drug candidate gotistobart ​led to a ​clinically meaningful overall survival ⁠benefit in ​a certain form of ​lung cancer compared with standard treatment.

MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial (NCT05671510) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”)...

BioNTech SE said on Friday it has ​decided to terminate the mid-stage trial ‌of its experimental mRNA-based cancer vaccine for patients with a type of colorectal cancer, ​sending the German firm's U.S.-listed ​shares down nearly 9%.

The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and ​Pfizer-BioNTech's updated COVID vaccines, the companies ‌said on Thursday, after an advisory panel recommended that the shots should target ​the dominant XFG variant.

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants Shipping will begin immediately to ensure rapid access to this season's vaccine  NEW YORK and MAINZ, GERMANY, August 27, 2026 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Admini...

MAINZ, Germany, August 20, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its diversified development program in lung cancer treatment at the IASLC 2026 World Conference on Lung Cancer (“WCLC”) in Seoul, Republic of Korea, from September 12-15, 2026.